Sign inJoin waitlistJoin the waitlist

Carrie B. Lee

Chief Medical Officer for UNC Lineberger Comprehensive Cancer Center Clinical Research

Credentials: · · ·

History

Basnight Cancer Hospital’s Clinical Trials Unit
Present
UNC School of Medicine
Present

University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
Northeastern Ohio Medical University
2002
The University of Akron

Research

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
Cancer Discovery · 2015 · 652 citations
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Nature · 2012 · 383 citations
Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy
Journal of Clinical Oncology · 2017 · 359 citations

MS
Mark Socinski
16 papers
Thomas Stinchcombe
14 papers
Frances Collichio
8 papers
Stergios Moschos
8 papers
Jared Weiss
7 papers
Neil Hayes
7 papers
JR
Julian Rosenman
6 papers
David Ollila
5 papers
Liza Villaruz
5 papers
Brian Jensen
4 papers
Chad Pecot
4 papers
David Morris
4 papers

Grants

Cancer Screening Research Network - North Carolina Hub (CSRN-NC HUB)
National Cancer Institute · UG1
PI · $3.3M · Univ of North Carolina Chapel Hill
2024–2027
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $5.1M · Univ of North Carolina Chapel Hill
1997–2027
Building Hybrid Operations to Promote Equity (HOPE) and Improve Clinical Trial Access Across North Carolina
Food and Drug Administration · U01
PI · $250K · Univ of North Carolina Chapel Hill
2024–2025

Clinical trials

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Principal investigator · Recruiting
UNC Lineberger Comprehensive Cancer Center
2025–2028
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Principal investigator · Completed · Phase 2
UNC Lineberger Comprehensive Cancer Center
2013–2020